PSPH and neoplasm: The neoantigen candidates arising from the PSPH: c.275+1del splice variant are predicted to be likely benign, but this mutation has been observed as a somatic mutation in several patients with tumor (cBioPortal), suggesting its potential relevance in tumor cells.